These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 17710443)

  • 1. Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis.
    Penel N; Dewas S; Doutrelant P; Clisant S; Yazdanpanah Y; Adenis A
    Support Care Cancer; 2008 Apr; 16(4):387-92. PubMed ID: 17710443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis on survival and prognostic factors for cancer patients with malignancy-associated hypercalcemia.
    Zhang SJ; Hu Y; Cao J; Qian HL; Jiao SC; Liu ZF; Tao HT; Han L
    Asian Pac J Cancer Prev; 2014 Jan; 14(11):6715-9. PubMed ID: 24377594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-associated hypercalcaemia in squamous-cell malignancies: a survival and prognostic factor analysis.
    Le Tinier F; Vanhuyse M; Penel N; Dewas S; El-Bedoui S; Adenis A
    Int J Oral Maxillofac Surg; 2011 Sep; 40(9):938-42. PubMed ID: 21489752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignancy associated hypercalcaemia-responsiveness to IV bisphosphonates and prognosis in a palliative population.
    Mallik S; Mallik G; Macabulos ST; Dorigo A
    Support Care Cancer; 2016 Apr; 24(4):1771-7. PubMed ID: 26441077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical analysis of 64 patients with lung-cancer-associated hypercalcemia.
    Li X; Bie Z; Zhang Z; Li Y; Hu X; Liu W; Zhang S; Cheng G; Ai B
    J Cancer Res Ther; 2015 Nov; 11 Suppl():C275-9. PubMed ID: 26612452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical characteristics and prognostic factors of malignancy-associated hypercalcemia in squamous cell carcinoma].
    Zhang SJ; Hu Y; Jiao SC; Liu ZF; Tao HT
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2012 Dec; 34(6):585-9. PubMed ID: 23286403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis of hypercalcemia in aerodigestive tract cancers: study of 136 recent cases.
    Penel N; Berthon C; Everard F; Neu JC; Clisant S; N'guyen M; Villet S; Fournier C; Lefebvre JL
    Oral Oncol; 2005 Oct; 41(9):884-9. PubMed ID: 16043379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
    Guay DR
    Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-associated hypercalcemia: validation of a bedside prognostic score.
    Penel N; Dewas S; Hoffman A; Adenis A
    Support Care Cancer; 2009 Aug; 17(8):1133-5. PubMed ID: 19290550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of hypercalcemia of tumoral origin with two diphosphonates].
    Jung A; van Ouwenaller C; Chantraine A; Courvoisier B
    Schweiz Med Wochenschr; 1980 Nov; 110(48):1822-4. PubMed ID: 6792698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of hypercalcemia of myelomatous origin with intravenous diphosphonates].
    Charhon S; Chapuy MC; Valentin-Opran A; Edouard C; Rosini S; Meunier PJ
    Presse Med; 1983 Dec; 12(47):2983-6. PubMed ID: 6228888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates--role in cancer therapies.
    Mehrotra B
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
    [No Abstract]   [Full Text] [Related]  

  • 13. Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy.
    Reagan P; Pani A; Rosner MH
    Am J Kidney Dis; 2014 Jan; 63(1):141-7. PubMed ID: 24021907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
    Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
    Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia.
    Nussbaum SR; Warrell RP; Rude R; Glusman J; Bilezikian JP; Stewart AF; Stepanavage M; Sacco JF; Averbuch SD; Gertz BJ
    J Clin Oncol; 1993 Aug; 11(8):1618-23. PubMed ID: 8336198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate.
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    J Bone Miner Res; 1986 Dec; 1(6):555-62. PubMed ID: 3503561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iv dichloromethylene diphosphonate in cancer-associated hypercalcemia: a phase I-II evaluation.
    Cohen AI; Koeller J; Davis TE; Citrin DL
    Cancer Treat Rep; 1981; 65(7-8):651-3. PubMed ID: 6454484
    [No Abstract]   [Full Text] [Related]  

  • 18. [New development in bisphosphonate treatment. Treatment with bisphosphonates for cancer-induced bone disease].
    Abe M
    Clin Calcium; 2009 Jan; 19(1):55-62. PubMed ID: 19122265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The incidence and management of bone metastasis from breast cancer].
    Saeki T; Ookubo K; Takeuchi H; Fujiuchi N
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1054-7. PubMed ID: 16912520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.
    Pecherstorfer M; Steinhauer EU; Rizzoli R; Wetterwald M; Bergström B
    Support Care Cancer; 2003 Aug; 11(8):539-47. PubMed ID: 12783289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.